Immunocore Holdings PLC IMCR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
45.84UNCH (UNCH)
Volume
1,271
Close
45.84quote price arrow up+0.84 (+1.87%)
Volume
203,804
52 week range
18.43 - 61.32
Loading...
  • Open44.23
  • Day High45.98
  • Day Low43.00
  • Prev Close45.00
  • 52 Week High61.32
  • 52 Week High Date09/09/22
  • 52 Week Low18.43
  • 52 Week Low Date01/21/22

Key Stats

  • Market Cap2.016B
  • Shares Out43.97M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change33.85

KEY STATS

  • Open44.23
  • Day High45.98
  • Day Low43.00
  • Prev Close45.00
  • 52 Week High61.32
  • 52 Week High Date09/09/22
  • 52 Week Low18.43
  • 52 Week Low Date01/21/22
  • Market Cap2.016B
  • Shares Out43.97M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change33.85

RATIOS/PROFITABILITY

  • EPS (TTM)-2.55
  • P/E (TTM)-17.98
  • Fwd P/E (NTM)-0.32
  • EBITDA (TTM)-93.078M
  • ROE (TTM)-47.45%
  • Revenue (TTM)72.94M
  • Gross Margin (TTM)80.90%
  • Net Margin (TTM)-136.99%
  • Debt To Equity (MRQ)41.11%

EVENTS

  • Earnings Date11/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Immunocore Holdings PLC

 

Profile

MORE
Immunocore Holdings plc, formerly Immunocore Holdings Ltd, is a late-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The Company is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced...
John Bell
Independent Chairman of the Board
Bahija Jallal Ph.D.
Chief Executive Officer, Director
Brian Di Donato
Chief Financial Officer, Head of Strategy
Address
90 Park Drive, Milton Park, Abingdon
Abingdon
OX14 4RY
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
RVNC
Revance Therapeutics Inc
25.67+0.73+2.93%
RXRX
Recursion Pharmaceuticals Inc
10.74-0.92-7.89%
IBRX
Immunitybio Inc
4.94-0.56-10.18%
FATE
Fate Therapeutics Inc
22.34-0.76-3.29%
ROIV
Roivant Sciences Ltd
3.17-0.16-4.80%